Yu D - Search Results

1

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, Viberti G; Diabetes Outcome Progression Trial (ADOPT) Study Group. Kahn SE, et al. Among authors: yu d. Diabetes Care. 2008 May;31(5):845-51. doi: 10.2337/dc07-2270. Epub 2008 Jan 25. Diabetes Care. 2008. PMID: 18223031 Free article. Clinical Trial.

2

Effect of selective screening for gestational diabetes.

Williams CB, Iqbal S, Zawacki CM, Yu D, Brown MB, Herman WH. Williams CB, et al. Among authors: yu d. Diabetes Care. 1999 Mar;22(3):418-21. doi: 10.2337/diacare.22.3.418. Diabetes Care. 1999. PMID: 10097921

3

Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes.

Kahn SE, Zinman B, Haffner SM, O'Neill MC, Kravitz BG, Yu D, Freed MI, Herman WH, Holman RR, Jones NP, Lachin JM, Viberti GC; ADOPT Study Group. Kahn SE, et al. Among authors: yu d. Diabetes. 2006 Aug;55(8):2357-64. doi: 10.2337/db06-0116. Diabetes. 2006. PMID: 16873701 Free article.

4

Low-dose rosiglitazone in patients with insulin-requiring type 2 diabetes.

Hollander P, Yu D, Chou HS. Hollander P, et al. Among authors: yu d. Arch Intern Med. 2007 Jun 25;167(12):1284-90. doi: 10.1001/archinte.167.12.1284. Arch Intern Med. 2007. PMID: 17592102 Clinical Trial.

5

Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT).

Kahn SE, Haffner SM, Viberti G, Herman WH, Lachin JM, Kravitz BG, Yu D, Paul G, Holman RR, Zinman B; Diabetes Outcome Progression Trial (ADOPT) Study Group. Kahn SE, et al. Among authors: yu d. Diabetes Care. 2010 Jan;33(1):177-83. doi: 10.2337/dc09-1661. Epub 2009 Oct 6. Diabetes Care. 2010. PMID: 19808911 Free PMC article. Clinical Trial.

6

Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy.

Yu D, Murdoch SJ, Parikh SJ, Marcovina SM, Cobitz A, Chen H, Brunzell JD. Yu D, et al. Diab Vasc Dis Res. 2006 Dec;3(3):189-96. doi: 10.3132/dvdr.2006.029. Diab Vasc Dis Res. 2006. PMID: 17160915 Free article. Clinical Trial.

7

Association of Sirtuin 1 Gene Polymorphisms with the Risk of Coronary Heart Disease in Chinese Han Patients with Type 2 Diabetes Mellitus.

Wang Y, Tong L, Gu N, Ma X, Lu D, Yu D, Yu N, Zhang J, Li J, Guo X. Wang Y, et al. Among authors: yu n, yu d. J Diabetes Res. 2022 Apr 16;2022:8494502. doi: 10.1155/2022/8494502. eCollection 2022. J Diabetes Res. 2022. PMID: 35469171 Free PMC article.

8

[Association between plasma osteopontin level and mild cognitive impairment in patients with type 2 diabetes mellitus].

Yu DD, Zhou XL, Niu DJ, Wang SH. Yu DD, et al. Zhonghua Yi Xue Za Zhi. 2024 Oct 15;104(38):3593-3599. doi: 10.3760/cma.j.cn112137-20240505-01041. Zhonghua Yi Xue Za Zhi. 2024. PMID: 39414588 Chinese.

9

Long-term use of proton pump inhibitors was associated with rapid progression to end stage kidney disease in a Korean nationwide study.

Lee YJ, Kim J, Yu DH, Je NK, Rhee H. Lee YJ, et al. Among authors: yu dh. Sci Rep. 2024 Dec 28;14(1):31477. doi: 10.1038/s41598-024-83321-7. Sci Rep. 2024. PMID: 39733180

10

High Incidence of syphilis seroconversion among people living with HIV in Hainan, south China.

Zhu K, Lu C, Yan H, Qiu Y, Qiao F, Zhang W, Yu D. Zhu K, et al. Among authors: yu d. Sci Rep. 2024 Dec 28;14(1):31432. doi: 10.1038/s41598-024-83097-w. Sci Rep. 2024. PMID: 39733157

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13,865 results

Search Page

Filters